In a report released today, Mark Massaro from BTIG maintained a Buy rating on MDxHealth (MDXH – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $2.97.
Massaro covers the Healthcare sector, focusing on stocks such as Exact Sciences, DermTech, and BioNano Genomics. According to TipRanks, Massaro has an average return of -15.4% and a 29.94% success rate on recommended stocks.
Currently, the analyst consensus on MDxHealth is a Strong Buy with an average price target of $7.00, representing a 135.69% upside. In a report released on March 7, TD Cowen also assigned a Buy rating to the stock with a $6.00 price target.
See the top stocks recommended by analysts >>
MDXH market cap is currently $81.05M and has a P/E ratio of -1.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MDxHealth (MDXH) Company Description:
MDxHealth SA engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, The Netherlands, Belgium, Spain, Poland, Italy, Rest of EU, and Rest of the World. It offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.
Read More on MDXH:
